EGFR-binding molecules and immunoconjugates thereof

US9125896B2 · kind B2 · utility

Assignee

• IMMUNOGEN, INC. · US

Inventors

• Julianto Setiady · Waltham, US
• Peter U. Park · Lexington, US
• Lingyun Rui · Weston, US
• Thomas Chittenden · Sudbury, US
• Gillian Payne · Newton, US

Key dates

• Filing date: Mar 13, 2013
• Grant date: Sep 8, 2015
• Expiry date: Jun 21, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.